Clinical update on the use of niacin for the treatment of dyslipidemia
- PMID: 15645997
- DOI: 10.1111/j.1745-7599.2004.tb00432.x
Clinical update on the use of niacin for the treatment of dyslipidemia
Abstract
Purpose: To provide nurse practitioners (NPs) with clinical and practical information about the use of niacin in the treatment of dyslipidemia.
Data sources: Research-based and review articles in the medical literature and National Cholesterol Education Program guidelines.
Conclusions: Niacin provides beneficial effects on all major lipid fractions, particularly high-density lipoprotein cholesterol and triglycerides. Niacin also reduces low-density lipoprotein (LDL) cholesterol; lipoprotein (a); and the number of highly atherogenic small, dense LDL particles. Niacin promotes angiographic regression when used in combination with other drugs that lower LDL cholesterol and can reduce cardiovascular risk in patients with coronary heart disease. Several niacin formulations are available, but the safety (i.e., from hepatotoxicity) and tolerability (i.e., severity of flushing) of these niacin formulations may differ.
Implications for practice: Niacin therapy is appropriate for many types of lipid abnormalities, including complex dyslipidemias. NPs can take several steps to minimize potential side effects of niacin therapy and to ensure that patients adhere to this important intervention.
Similar articles
-
Niacin for dyslipidemia: considerations in product selection.Am J Health Syst Pharm. 2003 May 15;60(10):995-1005. doi: 10.1093/ajhp/60.10.995. Am J Health Syst Pharm. 2003. PMID: 12789870
-
Niacin as a component of combination therapy for dyslipidemia.Mayo Clin Proc. 2003 Jun;78(6):735-42. doi: 10.4065/78.6.735. Mayo Clin Proc. 2003. PMID: 12934785 Review.
-
Niacin-based therapy for dyslipidemia: past evidence and future advances.Am J Manag Care. 2002 Sep;8(12 Suppl):S315-22. Am J Manag Care. 2002. PMID: 12240703 Review.
-
Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.Heart Dis. 2002 Mar-Apr;4(2):124-37. doi: 10.1097/00132580-200203000-00010. Heart Dis. 2002. PMID: 11975844 Review.
-
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.Am J Cardiovasc Drugs. 2008;8(2):69-81. doi: 10.2165/00129784-200808020-00001. Am J Cardiovasc Drugs. 2008. PMID: 18422390 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical